Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway.

Jellinger KA.

Mol Chem Neuropathol. 1991 Jun;14(3):153-97. Review.

PMID:
1958262
2.
3.
4.

Morphological substrates of dementia in parkinsonism. A critical update.

Jellinger KA.

J Neural Transm Suppl. 1997;51:57-82.

PMID:
9470129
5.

Morphological substrates of mental dysfunction in Lewy body disease: an update.

Jellinger KA.

J Neural Transm Suppl. 2000;59:185-212.

PMID:
10961431
6.

Neuropathological substrates of Alzheimer's disease and Parkinson's disease.

Jellinger K.

J Neural Transm Suppl. 1987;24:109-29. Review.

PMID:
3316494
7.

New developments in the pathology of Parkinson's disease.

Jellinger K.

Adv Neurol. 1990;53:1-16. Review.

PMID:
1978509
8.

Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease.

Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D.

Brain. 2014 Sep;137(Pt 9):2493-508. doi: 10.1093/brain/awu193.

9.
10.

Pathological basis for neurotransmitter changes in Parkinson's disease.

Mann DM, Yates PO.

Neuropathol Appl Neurobiol. 1983 Jan-Feb;9(1):3-19.

PMID:
6133229
11.

Ascending monoaminergic systems alterations in Alzheimer's disease. translating basic science into clinical care.

Trillo L, Das D, Hsieh W, Medina B, Moghadam S, Lin B, Dang V, Sanchez MM, De Miguel Z, Ashford JW, Salehi A.

Neurosci Biobehav Rev. 2013 Sep;37(8):1363-79. doi: 10.1016/j.neubiorev.2013.05.008. Review.

PMID:
23707776
12.

Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.

Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW.

Neuropharmacology. 2014 Jan;76 Pt A:97-105. doi: 10.1016/j.neuropharm.2013.08.033.

14.

Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases.

Gaspar P, Gray F.

Acta Neuropathol. 1984;64(1):43-52.

PMID:
6089493
15.

Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease.

Buddhala C, Loftin SK, Kuley BM, Cairns NJ, Campbell MC, Perlmutter JS, Kotzbauer PT.

Ann Clin Transl Neurol. 2015 Oct;2(10):949-59. doi: 10.1002/acn3.246.

16.
17.

Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease.

Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RG, Howe PR, Blessing WW, Geffen LB.

Ann Neurol. 1990 Apr;27(4):373-85.

PMID:
1972319
18.

Pattern of brain destruction in Parkinson's and Alzheimer's diseases.

Braak H, Braak E, Yilmazer D, de Vos RA, Jansen EN, Bohl J.

J Neural Transm (Vienna). 1996;103(4):455-90. Review.

PMID:
9617789
19.

Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.

Jellinger KA.

Acta Neuropathol. 2003 Sep;106(3):191-201. Erratum in: Acta Neuropathol (Berl). 2003 Dec;106(6):588.

PMID:
12845452
20.

The locus ceruleus and dementia in Parkinson's disease.

Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC.

Neurology. 1993 May;43(5):986-91.

PMID:
8492957
Items per page

Supplemental Content

Support Center